Want to see GB:OBI full AI Analyst Report?
OBI Stock Chart & Stats
11.75 p
0.25 p(1.82%)
At close: 4:00 PM EDT
11.75 p
0.25 p(1.82%)
Day’s Range― - ―
52-Week Range7.50 p - 16.00 p
Previous CloseN/A
Volume23.96K
Average Volume (3M)595.44K
Market Cap
£58.32M
Enterprise Value109.78M
Total Cash (Recent Filing)£10.58M
Total Debt (Recent Filing)£413.50K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding518,366,940
10 Day Avg. Volume1,146,586
30 Day Avg. Volume595,436
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)21.53
Price to Sales (P/S)28.32
P/FCF Ratio-3.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£12.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong recent revenue growth indicates improving commercial traction and increasing customer demand. If sustained, a larger revenue base could help absorb fixed costs, support operating leverage, and provide a foundation for the company to scale its antimicrobial technology over the next several quarters.
Low LeverageModest debt relative to equity provides some balance-sheet flexibility while the company remains in an investment and loss-making phase. Lower leverage can reduce fixed financing obligations and preserve more strategic room for funding clinical development, commercialization, or other growth priorities.
Clinical And Commercial ProgressProgress in clinical validation and adoption by a major NHS joint replacement centre supports the technology’s potential relevance in healthcare infection prevention. Further positive clinical outcomes or broader institutional uptake could strengthen credibility, accelerate commercialization, and expand future market access.
Bears Say
Severe UnprofitabilityThe scale of losses relative to revenue shows that the business has not yet demonstrated sustainable operating economics. Continued heavy investment without meaningful improvement in operating leverage could delay profitability, constrain strategic choices, and require additional capital before growth translates into durable earnings.
Worsening Cash BurnIncreasing cash outflows raise financing risk because the company must fund ongoing operations while revenue scales. Persistent negative operating and free cash flow can increase dependence on external capital, limit investment flexibility, and expose the business to disruption if funding is not secured on acceptable terms.
Gross Margin DeteriorationA sharp decline in gross margin weakens the quality of revenue growth and suggests that additional sales are currently producing less contribution toward operating costs. Unless margins recover, the company may need substantially higher revenue to reach breakeven, extending the period of losses and cash consumption.
Ondine Biomedical, Inc. News
OBI FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest share price was 7.50 p and its highest was 16.00 p in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is £58.32M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is Sep 30, 2026 which is in 23 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Jun 04, 2026. The company reported -0.019 p earnings per share for the quarter.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 518,366,940 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -0.019 p in its last earnings report. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in GB:OBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ondine Biomedical, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
Technical Analysis
Avacta Group plc
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Oxford Nanopore Technologies PLC
―